These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32415847)

  • 41. Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia.
    Bisol LW; Brunstein MG; Ottoni GL; Ramos FL; Borba DL; Daltio CS; de Oliveira RV; Paz GE; de Souza SE; Bressan RA; Lara DR
    J Clin Psychiatry; 2008 Oct; 69(10):1572-9. PubMed ID: 19192440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
    Marder SR; McQuade RD; Stock E; Kaplita S; Marcus R; Safferman AZ; Saha A; Ali M; Iwamoto T
    Schizophr Res; 2003 Jun; 61(2-3):123-36. PubMed ID: 12729864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Haloperidol dose for the acute phase of schizophrenia.
    Waraich PS; Adams CE; Roque M; Hamill KM; Marti J
    Cochrane Database Syst Rev; 2002; (3):CD001951. PubMed ID: 12137638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.
    Galling B; Roldán A; Rietschel L; Hagi K; Walyzada F; Zheng W; Cao XL; Xiang YT; Kane JM; Correll CU
    Expert Opin Drug Saf; 2016 May; 15(5):591-612. PubMed ID: 26967126
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
    Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
    Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.
    Kishi T; Ikuta T; Matsuda Y; Sakuma K; Iwata N
    Psychopharmacology (Berl); 2020 May; 237(5):1459-1470. PubMed ID: 32002559
    [TBL] [Abstract][Full Text] [Related]  

  • 48. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis.
    Sakuma K; Matsunaga S; Nomura I; Okuya M; Kishi T; Iwata N
    Psychopharmacology (Berl); 2018 Aug; 235(8):2303-2314. PubMed ID: 29785555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quetiapine versus typical antipsychotic medications for schizophrenia.
    Suttajit S; Srisurapanont M; Xia J; Suttajit S; Maneeton B; Maneeton N
    Cochrane Database Syst Rev; 2013 May; (5):CD007815. PubMed ID: 23728667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2021 Jun; 138():444-452. PubMed ID: 33964682
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
    Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
    Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does adding a second antipsychotic to clozapine improve clinical response in resistant schizophrenia?
    Jiménez-Cornejo M; Munizaga G; Aceituno D
    Medwave; 2016 Dec; 16(Suppl5):e6614. PubMed ID: 27922589
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia.
    Gao K; Pappadopulos E; Karayal ON; Kolluri S; Calabrese JR
    J Clin Psychopharmacol; 2013 Jun; 33(3):425-31. PubMed ID: 23609405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
    Potkin SG; Gharabawi GM; Greenspan AJ; Mahmoud R; Kosik-Gonzalez C; Rupnow MF; Bossie CA; Davidson M; Burtea V; Zhu Y; Trivedi JK
    Schizophr Res; 2006 Jul; 85(1-3):254-65. PubMed ID: 16797162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Jockers-Scherübl MC; Kühn KU; Lemke M; Bechdolf A; Bender S; Degner D; Schlösser R; Schmidt LG; Schmitt A; Jäger M; Buchkremer G; Falkai P; Klingberg S; Köpcke W; Maier W; Häfner H; Ohmann C; Salize HJ; Schneider F; Möller HJ;
    J Clin Psychiatry; 2007 Nov; 68(11):1763-74. PubMed ID: 18052570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
    Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
    Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.